GlassScriptPhysician profile
Kimberly K Oppman
NPI 1265507487
$5,122.00
in general payments reported to CMS, 2019-2025
20 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $550 · 2022: $616 · 2023: $1,007 · 2024: $1,328 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,956.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,837.74 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Paratek Pharmaceuticals, INC. | $585.66 | 2021-2025 | Nuzyra |
| Abbvie INC. | $553.80 | 2022-2025 | |
| Gilead Sciences, INC. | $510.56 | 2021-2025 | Biktarvy |
| Melinta Therapeutics, LLC | $418.59 | 2023-2025 | Rezzayo, Kimyrsa, Vabomere |
| Merck Sharp & Dohme LLC | $329.04 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Ferring Pharmaceuticals INC. | $150.83 | 2024-2025 | Rebyota |
| Theratechnologies INC. | $92.68 | 2023-2025 | Trogarzo, Egrifta |
| La Jolla Pharmaceutical Company | $90.82 | 2023 | Xerava |
| Aimmune Therapeutics, INC. | $85.28 | 2024-2025 | Vowst |
| Vanda Pharmaceuticals INC. | $69.16 | 2021 | |
| Emd Serono, INC. | $67.92 | 2024-2025 | |
| Astellas Pharma US INC | $65.62 | 2023-2025 | Cresemba |
| Napo Pharmaceuticals INC | $50.77 | 2021-2024 | Mytesi |
| Janssen Biotech, INC. | $48.02 | 2023 | Symtuza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $45.60 | 2023 | Fetroja |
| Octapharma USA, INC. | $40.83 | 2023-2024 | Octagam Immune Globulin (Human) |
| Vyera Pharmaceuticals, LLC | $34.74 | 2021 | |
| Pharming Healthcare, INC. | $24.56 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.78 | 2024 | Flumist Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Oppman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.